company background image
QUIA

QuiaPEG Pharmaceuticals Holding OM:QUIA Stock Report

Last Price

kr0.12

Market Cap

kr27.7m

7D

-6.4%

1Y

-77.6%

Updated

04 Dec, 2022

Data

Company Financials
QUIA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

QUIA Stock Overview

QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders.

QuiaPEG Pharmaceuticals Holding AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for QuiaPEG Pharmaceuticals Holding
Historical stock prices
Current Share Pricekr0.12
52 Week Highkr0.63
52 Week Lowkr0.052
Beta0.36
1 Month Change74.63%
3 Month Change17.00%
1 Year Change-77.59%
3 Year Changen/a
5 Year Change-94.03%
Change since IPO-97.29%

Recent News & Updates

Recent updates

Shareholder Returns

QUIASE BiotechsSE Market
7D-6.4%0.8%0.4%
1Y-77.6%-16.0%-21.3%

Return vs Industry: QUIA underperformed the Swedish Biotechs industry which returned -16% over the past year.

Return vs Market: QUIA underperformed the Swedish Market which returned -21.3% over the past year.

Price Volatility

Is QUIA's price volatile compared to industry and market?
QUIA volatility
QUIA Average Weekly Movement31.2%
Biotechs Industry Average Movement8.2%
Market Average Movement7.3%
10% most volatile stocks in SE Market12.4%
10% least volatile stocks in SE Market4.5%

Stable Share Price: QUIA is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 31% a week.

Volatility Over Time: QUIA's weekly volatility has increased from 19% to 31% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20124Marcus Bossonhttps://www.quiapeg.com

QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products.

QuiaPEG Pharmaceuticals Holding AB (publ) Fundamentals Summary

How do QuiaPEG Pharmaceuticals Holding's earnings and revenue compare to its market cap?
QUIA fundamental statistics
Market Capkr27.72m
Earnings (TTM)-kr22.19m
Revenue (TTM)kr5.54m

5.0x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
QUIA income statement (TTM)
Revenuekr5.54m
Cost of Revenuekr3.68m
Gross Profitkr1.86m
Other Expenseskr24.05m
Earnings-kr22.19m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.094
Gross Margin33.63%
Net Profit Margin-400.69%
Debt/Equity Ratio208.7%

How did QUIA perform over the long term?

See historical performance and comparison